Eledon Pharmaceuticals, Inc. Net Income (Loss) Available to Common Stockholders, Diluted
Eledon Pharmaceuticals, Inc. (ELDN) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$30.24 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-13
- Eledon Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was -$30.24M.
- Eledon Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was -$36.94M.
- Eledon Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was -$9.84M, a 146.31% decline year-over-year.
- Eledon Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was -$16.13M.
- Eledon Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for fiscal 2025 was -$42.33M.
- Eledon Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for fiscal 2024 was -$31.99M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$30.24M 10-Q · filed 2026-08-13 | -$67.22M 10-Q · filed 2026-08-13 | -$77.01M derived: sum of 3 quarters · filed 2026-08-13 | -$93.14M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2026-03-31 | -$36.94M 10-Q · filed 2026-05-13 | -$46.77M derived: sum of 2 quarters · filed 2026-05-13 | -$62.90M derived: sum of 3 quarters · filed 2026-05-13 | -$73.26M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-12-31 | -$9.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$25.97M derived: sum of 2 quarters · filed 2026-03-19 | -$36.33M derived: sum of 3 quarters · filed 2026-08-13 | -$42.33M 10-K · filed 2026-03-19 | ||
| 2025-09-30 | -$16.13M 10-Q · filed 2025-11-14 | -$26.49M derived: sum of 2 quarters · filed 2026-08-13 | -$32.49M 10-Q · filed 2025-11-14 | -$11.25M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-06-30 | -$10.36M 10-Q · filed 2026-08-13 | -$16.36M 10-Q · filed 2026-08-13 | $4.88M derived: sum of 3 quarters · filed 2026-08-13 | -$10.83M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-03-31 | -$6.00M 10-Q · filed 2026-05-13 | $15.24M derived: sum of 2 quarters · filed 2026-05-13 | -$465.00K derived: sum of 3 quarters · filed 2026-05-13 | -$39.50M derived: sum of 4 quarters · filed 2026-05-13 | ||
| 2024-12-31 | $21.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $5.54M derived: sum of 2 quarters · filed 2026-03-19 | -$33.50M derived: sum of 3 quarters · filed 2026-03-19 | -$31.99M 10-K · filed 2026-03-19 | ||
| 2024-09-30 | -$15.70M 10-Q · filed 2025-11-14 | -$17.50M 10-Q · filed 2024-11-12 | -$54.74M derived: sum of 2 quarters · filed 2025-11-14 | -$53.23M 10-Q · filed 2025-11-14 | -$61.09M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | -$39.03M 10-Q · filed 2025-08-14 | -$58.28M 10-Q · filed 2025-08-14 | ||||
| 2024-03-31 | -$19.50M 10-Q/A · filed 2025-08-14 | |||||
| 2023-09-30 | -$9.91M 10-Q · filed 2024-11-12 | -$86.44M 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |